Pneumonia Therapeutics Market Scope
Pneumonia is a severe form of an acute lower respiratory infection that specifically affects one of both lungs. It generally caused by bacteria, viruses or fungi. To treat pneumonia a variety of therapeutic targets have been identified and numerous innovative therapeutic approaches demonstrated to improve lung injury in experimental preclinical studies.
The market study is being classified by Type (Vaccines, Anti-Infectives and Oxygen Therapy), by Application (Hospital, Clinic, Medical Center and Other) and major geographies with country level break-up.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.
GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Novartis (Switzerland), Pfizer Inc. (United States), AstraZeneca plc (United Kingdom), Bayer AG (Germany), Biotest (Germany), Tetraphase Pharmaceuticals Inc. (United States), Eli Lilly and Company (United States) and Sanofi S.A. (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lupin Limited (India), Allergan plc (Ireland) and Baxter International Inc. (United States).
AdvanceMarketAnalytics has segmented the market of Global Pneumonia Therapeutics market by Type, Application and Region.
On the basis of geography, the market of Pneumonia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In February 2020, Merck has announced that the United States Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
- Increased Research and Development Activities
- Rise in the Number of Diagnostic Centres and Hospitals
- Increased Prevalence of Community-Acquired Pneumonia
- Improvements in the Diagnosis Methods
- Robust Increase in the Distribution Channels
- Increasing Awareness about Pneumonia Treatment among People
- Growth in the Healthcare Centre Worldwide
- Growing Number of Geriatric Population
- Increased Resistance of the Viruses to Various Antibiotics
- Lack of Healthcare Infrastructure in Under Developed Countries
- Stringent Government Rules and Regulations
- Lack of Skilled Professionals
Key Target AudiencePneumonia Therapeutics Providers, Research Professionals, Emerging Companies and End-users
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase